Christopher Gibson, MD, obtained his medical degree from Yale University School of Medicine, CT, in 2009 and trained as a resident in internal medicine at Brigham and Women’s Hospital, MA, where he was also Chief Medical Resident. He completed his fellowship in hemato-oncology at the Dana-Farber Cancer Institute, MA, in 2019 where he currently works as a Consultant.
Speaking on lymphoma, leukemia and ASCT
Dr Gibson’s research focuses on the treatment of leukemias, Hodgkin and non-Hodgkin lymphoma, and myelodysplastic and myeloproliferative diseases. His work has been centred around the effect of genetic mutations on patient outcomes amongst patients undergoing bone marrow transplants.